Using radiation and DNA damage response targeting to boost immune therapy for pancreatic cancer
Targeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy efficacy in pancreatic cancer
This study is looking at how combining certain drugs that help fix DNA damage with radiation therapy can make immunotherapy work better for people with pancreatic cancer, so they can have a stronger response against the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10796877 on NIH RePORTER |
What this research studies
This research investigates how targeting the DNA damage response (DDR) in pancreatic cancer can enhance the effectiveness of immunotherapy, particularly immune checkpoint blockade (ICB) therapy. The approach involves combining small molecule inhibitors that affect the DDR with radiation therapy to stimulate the immune system's response to cancer. By understanding the interactions between these treatments and the immune system, the research aims to improve patient outcomes in those with pancreatic ductal adenocarcinoma (PDAC). Patients may benefit from a more effective treatment strategy that leverages their own immune system to fight cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are seeking innovative treatment options.
Not a fit: Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with pancreatic cancer, potentially increasing survival rates and quality of life.
How similar studies have performed: Other research has shown promising results in combining radiation with immunotherapy, suggesting that this approach may be effective in enhancing treatment outcomes.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Morgan, Meredith a — University of Michigan at Ann Arbor
- Study coordinator: Morgan, Meredith a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.